Hutchmed spikes after cancer trial win despite 2024 revenue miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2025
0mins
Source: SeekingAlpha
Hutchmed's Trial Success: Hutchmed's cancer drug combination of sintilimab and fruquintinib successfully met its primary endpoint in the FRUSICA-2 trial, showing promise for treating renal cell carcinoma, despite the company reporting lower-than-expected revenue for 2024.
Financial Performance: Hutchmed's revenue for 2024 was approximately $630.2 million, falling short of forecasts by about $38.6 million, attributed to a depreciation of the Chinese currency against the U.S. dollar.
Analyst Views on HCM
Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.440
Low
22.00
Averages
22.00
High
22.00
Current: 15.440
Low
22.00
Averages
22.00
High
22.00
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
